Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium t…

发布时间：2023-07-17浏览数：794

Donanemab in Early Alzheimer's Disease

In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76…

发布时间：2021-05-06浏览数：640

Donanemab (LY3002813) dose-escalation study in Alzheimer's disease

Intravenous donanemab 10 mg/kg can reduce amyloid deposits in AD despite having a shorter than expected half-life.

发布时间：2021-02-14浏览数：788

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice

These studies have profound implications for the development of therapeutic Aβ antibodies for Alzheimer's disease.

发布时间：2012-01-06浏览数：756

Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques

A beta N3(pE) production and retention may play an early and critical role in senile plaque formation.

发布时间：1995-02-01浏览数：663